Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: A prospective european clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 2001-2011

  Kilday, John Paul ^a   Mitra, Biswaroop ^a   Domerg, Caroline ^c   Ward, Jennifer ^a   Andreiuolo, Felipe ^c   Osteso Ibanez, Teresa ^a   Mauguen, Audrey ^c   Varlet, Pascale ^d   Le Deley, Marie Cecile ^b   Lowe, James ^a,b   Ellison, David W ^e   Gilbertson, Richard J ^e   Coyle, Beth ^a   Grill, Jacques ^c   Grundy, Richard G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENE MAPPING; GENETIC GAIN; HUMAN; MALE; MEDICAL SOCIETY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TUMOR GROWTH;

ADOLESCENT; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EPENDYMOMA; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MICROARRAY ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859393684     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2489     Document Type: Article

References (34)

1. Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 2010;466:632-6.
2. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005;8:323-35. (Pubitemid 41443417)
3. Wright KD, Gajjar A. New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 2009;25:1275-82.
4. Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998;30:319-29; discussion 29-31.
5. Kilday JP, Rahman R, Dyer S, Ridley L, Lowe J, Coyle B, et al. Pediatric ependymoma: biological perspectives. Mol Cancer Res 2009;7:765-86.
6. Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007;8:696-705. (Pubitemid 47189085)
7. Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001;19:1288-96. (Pubitemid 32202532)
8. Massimino M, Gandola L, Giangaspero F, Sandri A, Valagussa P, Perilongo G, et al. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys 2004;58:1336-45. (Pubitemid 38438292)
9. Messahel B, Ashley S, Saran F, Ellison D, Ironside J, Phipps K, et al. Relapsed intracranial ependymoma in children in the UK: patterns of relapse, survival and therapeutic outcome. Eur J Cancer 2009;45:1815-23.
10. Zacharoulis S, Moreno L. Ependymoma: an update. J Child Neurol 2009;24:1431-8.
11. Andreiuolo F, Mauguen A, Kilday J-P, Modena P, Massimino M, Varlet P, et al. Tenascin-C is an independent prognostic marker in pediatric ependymoma: an International collaborative study (Abstract: ISPNO conference, Vienna 2010). Neuro-Oncology 2010;12:ii26.
12. Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002;86:929-39. (Pubitemid 34271030)
13. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 2010;28:3182-90.
14. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006;12:2070-9.
15. Dyer S, Prebble E, Davison V, Davies P, Ramani P, Ellison D, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002;161:2133-41. (Pubitemid 35434859)
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
17. Gnekow AK. Recommendations of the Brain Tumor Subcommittee for the reporting of trials. SIOP Brain Tumor Subcommittee. International Society of Pediatric Oncology. Med Pediatr Oncol 1995;24:104-8.
18. Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, et al. Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol 2011;13:866-79.
19. Rabbee N, Speed TP. A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics 2006;22:7-12. (Pubitemid 43057002)
20. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005;65:6071-9. (Pubitemid 40994391)
21. Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol 2011;13:212-22.
22. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-36.
23. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6. (Pubitemid 26342716)
24. Puget S, Grill J, Valent A, Bieche I, Dantas-Barbosa C, Kauffmann A, et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 2009;27:1884-92.
25. Bennetto L, Foreman N, Harding B, Hayward R, Ironside J, Love S, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol 1998;24:434-40. (Pubitemid 29002274)
26. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002;8:3054-64. (Pubitemid 35155014)
27. Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol 2008;10:675-89.
28. Duffner PK, Krischer JP, Sanford RA, Horowitz ME, Burger PC, Cohen ME, et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 1998;28:215-22. (Pubitemid 28402001)
29. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 2009;10:258-66.
30. Goldwein JW, Leahy JM, Packer RJ, Sutton LN, Curran WJ, Rorke LB, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 1990;19:1497-502.
31. Akyuz C, Emir S, Akalan N, Soylemezoglu F, Kutluk T, Buyukpamukcu M. Intracranial ependymomas in childhood-a retrospective review of sixty-two children. Acta Oncol 2000;39:97-100. (Pubitemid 30216623)
32. Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 2006;24:1522-8. (Pubitemid 46638773)
33. Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011;10:7.
34. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011;20:143-57.